The stock of ICU Medical, Incorporated (NASDAQ:ICUI) reached all time high today, Oct, 6 and still has $198.02 target or 41.00% above today’s $140.44 share price. This indicates more upside for the $2.27B company. This technical setup was reported by Barchart.com. If the $198.02 PT is reached, the company will be worth $930.70M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 625,885 shares traded hands or 568.30% up from the average. ICU Medical, Incorporated (NASDAQ:ICUI) has risen 36.99% since March 3, 2016 and is uptrending. It has outperformed by 28.64% the S&P500.
Analysts await ICU Medical, Incorporated (NASDAQ:ICUI) to report earnings on November, 3. They expect $0.92 earnings per share, up 5.75% or $0.05 from last year’s $0.87 per share. ICUI’s profit will be $14.88 million for 38.14 P/E if the $0.92 EPS becomes a reality. After $0.98 actual earnings per share reported by ICU Medical, Incorporated for the previous quarter, Wall Street now forecasts -6.12% negative EPS growth.
ICU Medical, Incorporated (NASDAQ:ICUI) Ratings Coverage
Out of 4 analysts covering ICU Medical (NASDAQ:ICUI), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. ICU Medical has been the topic of 8 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Piper Jaffray maintained the shares of ICUI in a report on Tuesday, August 11 with “Overweight” rating. The firm has “Buy” rating by Roth Capital given on Tuesday, August 11. The rating was maintained by Roth Capital on Friday, November 6 with “Buy”. The stock of ICU Medical, Incorporated (NASDAQ:ICUI) has “Buy” rating given on Friday, November 6 by TH Capital. TH Capital maintained it with “Buy” rating and $124 target price in Tuesday, August 11 report. On Monday, August 17 the stock rating was upgraded by Zacks to “Hold”. The stock of ICU Medical, Incorporated (NASDAQ:ICUI) earned “Buy” rating by Gabelli on Friday, March 11.
According to Zacks Investment Research, “ICU Medical, Inc., together with its wholly-owned subsidiary Budget Medical Products, Inc. is a leader in the development, manufacture and sale of proprietary, disposable medical connection systems for use in intravenous therapy applications. The company’s intravenous connectors are designed to prevent accidental disconnection’s of intravenous lines and to protect healthcare workers and their patients from the spread of infectious diseases such as Hepatitis B and Human Immunodeficiency Virus by significantly reducing the risk of accidental needlesticks.”
Insitutional Activity: The institutional sentiment increased to 1.02 in Q2 2016. Its up 0.11, from 0.91 in 2016Q1. The ratio increased, as 14 funds sold all ICU Medical, Incorporated shares owned while 76 reduced positions. 20 funds bought stakes while 72 increased positions. They now own 14.20 million shares or 0.50% more from 14.13 million shares in 2016Q1.
Jpmorgan Chase & last reported 309,998 shares in the company. State Of Tennessee Treasury Department accumulated 11,265 shares or 0.01% of the stock. Tudor Investment Et Al last reported 0.01% of its portfolio in the stock. Adams Diversified Equity Fund reported 3,900 shares or 0.03% of all its holdings. Natl Bank Of Nova Scotia has 23,357 shares for 0.02% of their US portfolio. First Fincl In reported 200 shares or 0.01% of all its holdings. The Texas-based Employees Retirement System Of Texas has invested 0.07% in ICU Medical, Incorporated (NASDAQ:ICUI). Blackrock Advsrs Limited Co holds 78,067 shares or 0.01% of its portfolio. Systematic Mgmt L P last reported 0.03% of its portfolio in the stock. Whittier, a California-based fund reported 120 shares. Qs Invsts Limited Company last reported 0.05% of its portfolio in the stock. Eaton Vance has 0.05% invested in the company for 156,621 shares. Barton Invest Mgmt has 0.18% invested in the company for 4,275 shares. The New York-based Tower Research Cap (Trc) has invested 0.01% in ICU Medical, Incorporated (NASDAQ:ICUI). The New York-based Markston Intll Limited Co has invested 0% in ICU Medical, Incorporated (NASDAQ:ICUI).
Insider Transactions: Since April 11, 2016, the stock had 0 insider buys, and 15 selling transactions for $16.94 million net activity. Shares for $2.31 million were sold by McCall Thomas D on Friday, August 12. The insider SWINNEY ROBERT S sold 1,875 shares worth $190,031. $1.00M worth of ICU Medical, Incorporated (NASDAQ:ICUI) shares were sold by SAUCEDO JOSEPH R. SHERMAN RICHARD MD also sold $367,530 worth of ICU Medical, Incorporated (NASDAQ:ICUI) shares. Sanzone Virginia Ruth had sold 1,903 shares worth $230,824 on Wednesday, August 24. Another trade for 7,268 shares valued at $903,019 was sold by Jain Vivek. 1,474 shares were sold by Lamb Scott E, worth $179,255.
More recent ICU Medical, Incorporated (NASDAQ:ICUI) news were published by: Streetinsider.com which released: “ICU Medical (ICUI) to Acquire Pfizer’s (PFE) Hospira Infusion Systems Business …” on October 06, 2016. Also Reuters.com published the news titled: “ICU Medical to buy Pfizer’s infusion therapy business for $1 bln” on October 06, 2016. Prnewswire.com‘s news article titled: “B. Braun and ICU Medical Sign Expanded Long-Term International Distribution …” with publication date: March 21, 2016 was also an interesting one.
ICUI Company Profile
ICU Medical, Inc., incorporated on January 9, 1992, is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The Firm operates through the segment, which is engaged in the development, manufacturing and sale of medical technologies used in infusion therapy, critical care and oncology applications. The Company’s products are used in acute care hospitals and ambulatory clinics in over 60 countries around the world.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.